For patients with certain types of advanced lung or skin cancer, administration of SARS-CoV-2 mRNA vaccine within 100 days of starting ICIs is associated with increased overall survival.

Vaccine manufacturing is challenged by stringent global regulations, essential for ensuring safety and efficacy, with ...

Strand Therapeutics promotes Prashant Nambiar to CSO and appoints Ethan Cash as SVP, Head of Portfolio Management and Program ...

Lipid-based nanoparticles are pivotal in modern medicine, improving drug delivery and mRNA therapies through innovative ...

The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients by boosting their immune systems to help fight tumors. Research reported recently in the journal Nature ...

The U.S. government is turning its back on a medical breakthrough that has saved millions of lives, halting $500 million in federal funding to develop new mRNA vaccines against potentially ...

Children and young people have higher risks of rare vascular and inflammatory diseases up to 12 months after a first COVID-19 ...

Ionis Pharmaceuticals, Inc. shows promise with new drug launches and a robust pipeline. Click here to read IONS stock ...

Moderna (MRNA) just began dosing patients in a Phase 1/2 study of mRNA-2808, its experimental T-cell therapy for advanced multiple myeloma. This effort highlights Moderna's growing emphasis on cancer ...

The official opening will be headlined by Dr Nomalungelo Gina, Deputy Minister of Science, Technology and Innovation, who ...

Q3 2025 Earnings Call Transcript November 3, 2025 BioNTech SE misses on earnings expectations. Reported EPS is $-0.14 EPS, expectations were $0.75. Operator: Welcome to BioNTech’s Third Quarter 2025 ...

The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...